I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Naz Rahman reiterated a Buy rating on Xtant Medical Holdings with a $1.50 price target, citing the BioHorizons partnership and high-margin OsteoFactor Pro as key growth drivers. Despite unchanged financial estimates, Rahman notes Xtant's valuation discount to peers supports the positive stance. TipRanks data shows Rahman has a -5.5% average return. Separately, Craig-Hallum assigned a Buy rating with a $0.60 target.
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Xtant Medical Holdings, with a price target of $1.50.
Naz Rahman has given his Buy rating due to a combination of factors tied to Xtant’s growth strategy and product mix. He views the exclusive partnership with BioHorizons, backed by Henry Schein’s expansive global dental network, as a catalyst that can rapidly expand OsteoFactor Pro’s penetration in dental and oral‑maxillofacial markets under the Prolifica private label brand.
He also highlights that OsteoFactor Pro is already a major driver of both revenue and gross margin, benefiting from substantially higher pricing and margins than traditional allograft products, and sees room to extend the partnership to additional Xtant offerings. Despite leaving financial estimates unchanged, he notes that Xtant trades at a notable EV/EBITDA discount to peers and that his valuation work supports a 12‑month price target above the current share price, reinforcing his positive stance on the stock.
According to TipRanks, Rahman is an analyst with an average return of -5.5% and a 38.63% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vivani Medical, Nuvectis Pharma, and Vertex Pharmaceuticals.
In another report released on August 12, Craig-Hallum also assigned a Buy rating to the stock with a $0.60 price target.